Physician profile
Alex Schmidt
NPI 1669925756
$10,002.43
in general payments reported to CMS, 2019-2025
33 companies · $1,758 in 2025
The $1,758 reported for 2025 was more than what 84% of Pain Medicine (Physical Medicine & Rehabilitation) providers received nationally (typical 2025 total: $400).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $2,110 · 2021: $461 · 2022: $487 · 2023: $2,331 · 2024: $2,856 · 2025: $1,758.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,924 · Education: $20.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,923.93 |
| Education | $20.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,883.42 | 2023-2025 | Proclaim, Octrode, Eterna |
| Medtronic USA, INC. | $1,711.23 | 2020 | |
| Abbvie INC. | $919.63 | 2023-2025 | Botox, Ubrelvy, Qulipta |
| Boston Scientific Corporation | $635.52 | 2020-2023 | Wavewriter Alpha Prime 16 |
| Tersera Therapeutics LLC | $288.98 | 2022-2025 | Prialt |
| Ucb, INC. | $286.74 | 2023-2025 | Cimzia, Bimzelx |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $284.37 | 2022-2025 | Relistor |
| Medtronic, INC. | $266.19 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $221.23 | 2023-2025 | Saphnelo, Breztri |
| Spinefrontier, INC. | $212.30 | 2024 | Inspan, Sijfuse |
| Collegium Pharmaceutical, INC. | $211.70 | 2021-2025 | Belbuca, Xtampza |
| Grt US Holding, INC. | $143.90 | 2021-2022 | |
| Averitas Pharma INC. | $129.86 | 2024-2025 | Qutenza |
| Curonix LLC | $90.21 | 2023-2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Scilex Pharmaceuticals INC. | $82.20 | 2022-2025 | Ztlido |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $75.05 | 2022-2024 | Senza |
| Azurity Pharmaceuticals, INC. | $69.83 | 2023-2025 | Horizant, Horizant |
| Amgen INC. | $63.88 | 2022-2024 | Repatha |
| Lundbeck LLC | $63.30 | 2024-2025 | Vyepti |
| Saluda Medical Americas, INC. | $52.21 | 2022-2025 | Evoke |
| Ibsa Pharma INC. | $47.70 | 2022-2024 | Flector, Licart, Tirosint |
| Protega Pharmaceutials INC | $34.58 | 2025 | Roxybond |
| Painteq LLC | $31.17 | 2023 | Painteq |
| Allergan, INC. | $27.76 | 2022 | |
| Merz Pharmaceuticals, LLC | $24.36 | 2024 | Xeomin |
| Axsome Therapeutics, INC. | $23.36 | 2025 | Symbravo |
| Horizon Therapeutics Plc | $19.89 | 2023 | Krystexxa |
| Shield Therapeutics INC | $19.75 | 2024 | |
| Relievant Medsystems, INC. | $18.58 | 2023 | Intracept |
| Depuy Synthes Sales INC. | $18.52 | 2024 | Orthovisc, Monovisc |
| Amneal Pharmaceuticals LLC | $15.68 | 2023 | Lyvispah |
| Hikma Pharmaceuticals USA | $14.69 | 2024 | Kloxxado |
| Aurinia Pharma U.S., INC. | $14.64 | 2024 | Lupkynis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alex Schmidt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.